Canadian Association for Clinical Microbiology and Infectious Diseases

Dr. Michael R. Mulvey CACMID Studentship Award

The Dr. Michael R. Mulvey CACMID Studentship Award recognizes Canadian trainees that have made a noteworthy contribution to antimicrobial resistance in the form of a recently published article.

This inaugural honour (2023) will be awarded each year (depending on available funds) at the annual AMMI-CACMID meeting. The award includes a monetary value of $800 and a commemorative plaque. The recipient will be invited to the CACMID annual meeting to receive the award. Registration cost will be reimbursed.

Nominations may be submitted at any time prior to the February deadline, preceding the annual meeting. The CACMID Awards and Nominations committee will review the applications and announce the winner at the Awards ceremony at the annual meeting.

Applicant eligibility

Publication requirements

Applications must include

  1. A letter of support describing the noteworthy contribution of the article and the nominee’s role in the article (up to 1 page)
  2. A letter of attestation from institution indicating enrolment in training program
  3. PDF of the article

Dr. Michael R. Mulvey is a renowned expert on antimicrobial resistance (AMR) in Canada and around the world. Dr. Mulvey started working for Health Canada, now the National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC) in 1996, where he established and is the Chief of the Antimicrobial Resistance and Nosocomial Infections (ARNI) Laboratory. One of the primary functions of this laboratory is to provide support for reference activities, surveillance programs, and outbreak support, including work with provincial public health laboratories and hospitals across Canada on programs such as the: University of Manitoba CANWARD Surveillance Program; The Canadian Nosocomial Infection Surveillance Program (CNISP); The Canadian Integrated Program on Antimicrobial Resistance Surveillance (CIPARS); and Streptococcal and Sexually Transmitted Infections Laboratory Surveillance. He also recently established NML’s National Reference Laboratory for Mycology (2016), Wasterwater Surveillance Laboratory (2020), and a new national surveillance program to capture electronic AMR data generated from all human and veterinary laboratories called AMRNet (2021).

Dr. Mulvey has a reputation as a world-leading AMR scientist and his expertise is greatly sought after. He generously volunteers his time on many AMR expert committees including the: Canadian Public Health Laboratory Network Working Group on AMR; Executive Board of the Canadian Committee on Antimicrobial Susceptibility Testing (CANCAST); European Committee on Antimicrobial Susceptibility Testing (EUCAST) (subcommittee for WGS-AMR); US National Antimicrobial Resistance Monitoring System (molecular epidemiology working group); three Transatlantic Task Force Committees on AMR working groups; Medical Countermeasures Consortium (UK/US/Canada/Australia) Task Group on Antimicrobials; and the Canadian Institutes for Health Research Institute of Infection and Immunity Institute Advisory Board. Dr. Mulvey has received numerous awards including the 2022 PHAC Chief Public Health Officer Medal, 2020 CACMID John G. FitzGerald Award, 2015 Honorary Membership in the Association of Medical Microbiology and Infectious Diseases (AMMI Canada), and the 2016 University of Manitoba Faculty of Science Honoured Alumni of the Year, among others.

His research interests include the molecular mechanisms and epidemiology of AMR and the translation of resistance data into interventions to limit the spread of resistant organisms and improve public health. Some of his current research includes: (1) Improved diagnostics for AMR detection; (2) Improved antimicrobial treatment options for highly antimicrobial resistant pathogens; (3) Characterizing novel AMR genes and emerging pathogens (4) Use of whole genome sequencing for AMR surveillance, diagnostics and outbreaks. His research activities have resulted in authorship/co-authorship of over 320 peer-reviewed publications. He continuously builds upon his program through grant applications/projects, interdepartmental-funded projects and continues to build Canadian laboratory capacity for the study of AMR. Since 2010, his collaborations have resulted in successfully competing for over $1.7 M in funding from national and international agencies and $3.7M in internal government peer-reviewed funding.

As a mentor, Dr. Mulvey has extensively contributed to the field by sharing his expertise. He has supervised/co-supervised over 50 Masters students/post-doctoral fellows/co-op students and participated in over 20 graduate student thesis advisory committees. In conjunction with his mentorship, he has served as an adjunct professor at the University of Manitoba, University of Calgary, University of Guelph and as of 2019, Professor in the Department of Medical Microbiology, University of Manitoba.

Dr. Mulvey’s tireless work, determination and dedication to excellence ensures that his work on AMR is making significant advancements in our understanding of the dissemination of antibiotic resistant organisms and how to limit the spread of AMR in Canada and throughout the world.

Terms of Reference for the Dr. Michael Mulvey CACMID Studentship Award

Goal: The CACMID Awards and Nominations committee is responsible for the promotion and preservation of this award as a highly prestigious recognition of a Canadian trainee that has made a noteworthy contribution to the study of antimicrobial resistance.

Award: A monetary value of $800 and a commemorative plaque.

Award Process:

Dr. Michael R. Mulvey CACMID Studentship Award Recipients

2023 – Domenica de Luca: Four genomic clades of Candida auris identified in Canada, 2012–2019